In fact, inhibition of receptor tyrosine kinases including the epidermal growth factor receptor (EGFR) and HER2 in experimental cancer models can trigger feedback activation of STAT3 as a possible mechanism of resistance to targeted therapies (Zhao et al., 2016). Here, NTRK1 is linked to cancer.